TLC-ART’s innovative technology has now been validated to enable to produce long-acting, targeting multiple drugs simultaneously to HIV-host cells, & to allow a single-dose to carry 3-4 drugs. The following boxes demonstrate platform capabilities and validation.
3-Drug Combo b: LPV/RTV/TFV
- 3 drugs in 1 nano-dosage
- One SQ dose last for 2+ wk
- HIV host cells > plasma drugs
- Lymph cells > PBMC c
Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
4-Drug Combo b: LPV/RTV/3TC/TFV
- 4 drugs in 1 nano-dosage
- One SQ dose last for 2+ wk
- HIV host cells > plasma drugs
- Lymph cells > PBMC c
3-Drug Combo b: ATV/RTV/TFV
- 3 drugs in 1 nano-dosage
- One SQ dose last for 2+ wk
- HIV host cells > plasma drugs
- Lymph cells > PBMC c
Three HIV Drugs Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
3-Drug Combo b: LPV/EFV/TFV
- 3 drugs in 1 nano-dosage
- One SQ dose last for 2+ wk
- HIV host cells > plasma drugs
- Lymph cells > PBMC c
a, DcNP; Drug combination Nano-Particle platform developed by the TLC-ART Program
b, LPV, Lopinavir; RTV, Ritonavir; 3TC, Lamivudine; EFV, Efavirenz; TFV, Tenofovir
c, PBMC found in the blood that can be HIV infected